A short history of anti-rheumatic therapy VIII. The immunosuppressants

Reumatismo

Volumn 64, Issue 1, 2012, Pages 44-54

  Pasero, G ^a   Marson, Piero ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Azathioprine; Cyclophosphamide; Cyclosporin A; History of rheumatology; Immunosuppressive drugs; Methotrexate; Mycophenolate mofetil; Thalidomide

Indexed keywords

ALLOPURINOL; AMINOPTERIN; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; FOLIC ACID; IMIDAZOLE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SMALLPOX VACCINE; THALIDOMIDE; ALKYLATING AGENT; ANTIMETABOLITE; FOLIC ACID ANTAGONIST; MYCOPHENOLIC ACID;

AORTA ARCH SYNDROME; ARTICLE; CLINICAL PRACTICE; DERMATOMYOSITIS; DRUG INFORMATION; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; GRAFT REJECTION; HUMAN; HYPERURICEMIA; LEUKEMIA; PATHOLOGICAL ANATOMY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION; ANALOGS AND DERIVATIVES; ART; CLASSIFICATION; HISTORY; IMMUNOLOGY; RHEUMATIC DISEASES;

ALKYLATING AGENTS; ALLERGY AND IMMUNOLOGY; ANTIMETABOLITES; ANTIRHEUMATIC AGENTS; CYCLOSPORINE; FOLIC ACID ANTAGONISTS; GRAFT REJECTION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; RHEUMATIC DISEASES; THALIDOMIDE;

EID: 84875910818     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: 10.4081/reumatismo.2012.44     Document Type: Article

References (97)

1. Klinge F. Der Rheumatismus: patologischeanatomische und experimentellpatologische Tatsachen und ihre Auswertung für das ärztliche Rheumaproblem. Ergebn Allg Path path Anat. 1933; 27: 1-336.
2. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand. 1940; 17: 172-88.
3. Rose HM, Ragan C, Pearce C, Lipman MO. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med. 1948; 68:1-6.
4. Hargraves MM, Richmond H, Harrison R. Presentation of two new marrow elements: 'tart cell' and 'LE cell'. Proc Staff Meet Mayo Clin. 1948; 23: 25-8.
5. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc Bayl Univ Med Cent. 2005; 18: 21-5.
6. Pontecorvo M. Storia delle vaccinazioni. Origgio (VA), Ciba-Geigy Edizioni. 1991; 30-53.
7. Osborne ED, Jordan JW, Hoak FC, Pschierer FJ. Nitrogen mustard therapy in cutaneous blastomatous disease. JAMA. 1947; 135: 1123-8.
8. Gubner R, August S, Ginsburg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci. 1951; 221: 176-82.
9. Jimenez-Diaz C. Treatment of dysreaction diseases with nitrogen mustards. Ann Rheum Dis. 1951; 10: 144-52.
10. Miescher PA. Immunosuppressive therapy. Proceedings of the Wiesbaden International Symposium on Immunosuppressive Therapy, 1972. New York, International Medical Book Corp. 1983.
11. Schwartz RS, Gowans JD. Guidelines for the use of cytotoxic drugs in rheumatic diseases. Arthritis Rheum. 1971; 14: 134-7.
12. Silverman WA. The schizofrenic career of a "monster drug". Pediatrics 2002; 110: 404-6.
13. Pasero G, Marson P. Piccola storia della terapia antireumatica-VI. I farmaci dell'artrite reumatoide. Reumatismo. 2011; 63: 111-23.
14. Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide. Emphasis on use in rheumatic diseases. Semin Arthritis Rheum. 1983; 12: 359-68.
15. Giua M, Giua-Lollini C. Dizionario di chimica generale e industriale. Torino, UTET. 1948; 1: 326.
16. Krumbhaar EB, Krumbhaar HD. The blood and the bone marrow in yellow cross gas (mustard gas) poisoning: changes produced in the bone marrow of fatal cases. J Med Res. 1919; 40: 497-508.
17. Berenblum I. The modifying influence of dichloroethyl sulphide on the induction of tumours in mice by tar. J Pathol Bacteriol. 1929; 32: 425-34.
18. Papac RJ. Origins of cancer therapy. Yale J Biol Med. 2001; 74: 391-8.
19. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg. 1963; 105: 574-8.
20. rded. 1993; 276.
21. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan. Nitrogen mustard therapy. Use of methyl-bis(betachloroethyl(amine hydrochloride and tris(betachloroethylamine hydrochloride in the treatment of Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. JAMA. 1946; 105: 475-6 (riprodotto anche in JAMA. 1984; 251: 2255-61).
22. Brock N. The history of oxazaphosphorine cytostatics. Cancer. 1996; 78: 542-7.
23. Arnold H, Bourseaux F, Brock N. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518 ASTA). Nature. 1958; 181: 931.
24. Stender HS, Ringleb D, Strauch D, Winter H. Die Beinflussding der Antikörper-Bildung durch Zytostatika und Röntgenbestrahlung. Strahlentherapie. 1959; (Suppl. 43): 392-9.
25. Fosdick WM, Parsons JL, Hill DF. Long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum. 1968; 11: 151-61.
26. Schultz EJ, Menter MA. Treatment of discoid and subacute lupus erythematosus with cyclophosphamide. Br J Dermatol. 1971; (Suppl. 7): 60-5.
27. Fauci AS, Wolff SM. Wegener's granulomatosis. Studies in eighteen patients and review of the literature. Medicine (Baltimore) 1973; 52: 535-61 (riprodotto anche in Medicine. 1994; 73: 315-24).
28. Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH, Steinberg AD. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med. 1982; 96: 728-36.
29. Levy L, Chia D, Barnett EV. Effect of pulse dose cyclophosphamide on the anamnestic immune response in NZB/W mice. Agent Actions. 1978; 8: 644-51.
30. 1N-di-2-chloroethylaniline. J Chem Soc. 1953; 3: 2386-92.
31. Wills L. Treatment of 'pernicious anaemia of pregnancy' and 'tropical anemia', with special reference to yeast extract as a curative agent. Br Med J. 1931; i: 1059-64.
32. Hoffbrand AV, Weir DG. The history of folic acid. Br J Haematol. 2001; 113: 579-89.
33. Mitchell HK, Snell EE, Williams RJ. The concentration of 'folic acid'. J Am Chem Soc. 1941; 63: 2284-7 (riprodotto anche in Nutr Rev. 1988; 46: 324-5).
34. Hogan AG, Parrot EM. Anaemia in chicks caused by a vitamin deficiency. J Biol Chem. 1940; 132: 507-17.
35. Snell EE, Peterson WH. Growth factors for bacteria. X. Additional factors required by certain lactic acid bacteria. J Bacteriol. 1940; 39: 273-85.
36. Day PL, Langston WC, Darby WJ, Wahlin JG, Mims V. Nutritional cytopenia in monkeys receiving the goldberger diet. J Exp Med. 1940; 72: 463-77.
37. Angier RB, Boothe JH, Hutchings BL, Mowat JH, Semb J, Stokstad ELR, Subbarow J, Waller CW, Cosulich DB, Fahrenbach MJ, Hultquist ME, Kuh E, Northey EH, Seeger DR, Sickels JP, Smith JM jr. Synthesis of a compound identical with the L. casei factor isolated from the liver. Science. 1945; 102: 227-8.
38. Spies TD, Vilter CF, Koch MB, Caldwell MH. Further studies on folic acid in the treatment of macrocytic anemia. South Med J. 1945; 38: 781-5.
39. Shive W, Bardos TJ, Bond TJ, Rogers LL. Synthetic members of the folinic acid group. J Am Chem Soc 1950; 72: 2817-8.
40. Seeger DR, Smith JM jr, Hultquist ME. Antagonist for pteroylglutamic acid. J Am Chem Ass. 1947; 69: 2567.
41. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remission in acute leukemia in children produced by folic antagonist 4-amethopteroylglutamic acid (aminopterin). N Engl J Med. 1948; 238: 787-93.
42. Gubner R, Cote L, Hughes J, Oleson JJ, Ruegsegger JM, Williams JH. Comparative effects of aminopterin, cortisone and ACTH in experimental formaldehyde arthritis and psoriatic arthritis. J Invest Dermatol. 1952; 19: 297-305.
43. Kersley GD. Amethopterin (methotrexate) in connective tissue disease-psoriasis and polyarthritis. Ann Rheum Dis. 1968; 27: 64-6.
44. Smith JM jr, Cosulich DB, Hultquist ME, Seeger DR. The chemistry of certain pteroylglutamic acid antagonists. Trans NY Acad Sci. 1948; 10: 82-3.
45. Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med 1958, 259: 66-74.
46. O'Brien WM, Van Scott EJ, Black RL, Eisen AZ, Bunim JJ. Clinical trial of amethopterin (methotrexate) in psoriatic and rheumatoid arthritis (preliminary report). Arthritis Rheum. 1962; 5: 312 (Abstr).
47. Hoffmeister RT. Methotrexate in rheumatoid arthritis. Arthritis Rheum. 1972; 15: 114 (Abstr).
48. Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, Carlin G, Huie MA, Cronstein BN. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires 5′-ectonucleotidase conversion of adenosine nucleotides. J Clin Invest. 1998; 101: 295-300.
49. Benedek TG. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-T. Clin Exp Rheumatol. 2010; 28 (Suppl 61): S3-8.
50. Smythe CJ. Therapy of rheumatoid arthritis: a pyramidal plan. Postgrad Med. 1972; 51: 31-9.
51. Wilske KR, Healey LA. Remodeling the pyramid-a concept whose time has come. J Rheumatol. 1989; 16: 565-7.
52. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2000; 2: CD000957.
53. Elion GB. The purine path to chemotherapy. Science. 1989; 244: 41-7.
54. Armistead GC Jr, Burchenal JH, Karnofsky D, Southam CM. Preliminary studies on the clinical toxicity of 5-amino-7hydroxy-1-vtriazolo(d)pyrimidine (guanazolo). Cancer N.Y. 1949; 2: 1087-8.
55. Burchenal JH, Bendich A, Brown GB, Elion GB, Hitchings GGH, Rhoads CP, Stock CC. Preliminary studies on the effect of 2,6-diaminopurine on transplanted mouse leukemia. Cancer N.Y. 1949; 2: 119-20.
56. Elion GB, Burgi E, Hitchings GH. Studies on condensed pyrimidine system. IX. The synthesis of some 6-substituted purines. J Am Chem Ass. 1952; 74: 411-4.
57. Damashek W, Schwartz R. Treatment of certain "autoimmune" diseases with antimetabolites: a preliminary report. Trans Assoc Am Physicians. 1960; 73: 113-27.
58. Skinner MD, Schwartz RS. Immunosuppressive therapy. 1. N Engl J Med. 1972; 287: 221-7.
59. Elion GB, Callahan SW, Bieber S, Hitchings GH, Rundles RW. A summary of investigations with 6-(1-methyl-4-nitro-g-imidazolylthio) purine (B.W. 57-323). Cancer Chemother Rep. 1961; 14: 93-8.
60. Hitchings GH, Elion GB. Chemical suppression of the immune response. Pharmacol Rev. 1963; 15: 365-405.
61. Hitchings GH. Daraprim as an antagonist of folic and folinic acids. Trans R Soc Trop Med Hyg. 1952; 46: 467-73.
62. Roth B, Falco EA, Hitchings GH, Bushby SR. 5-benzyl-2,4-diaminopirymidines as antibacterial agents. I. Synthesis and antibacterial activity in vitro. J Med Pharm Chem. 1962; 91: 1103-23.
63. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA. 1977; 74: 5716-20.
64. Mitsuya H, Weinhold KJ, Furman PA, StClair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. 3′-azido-3′deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-100.
65. Rundles RW. The development of allopurinol. Arch Intern Med. 1985; 145: 1492-503.
66. Raju TN. The Nobel chronicles. 1988: James Whyte Black (b 1924), Gertrude Elion (1918-99) and George H. Hitchings (1905-98). Lancet. 2000; 355: 1022.
67. Haddow A, Timmis GM. Bifunctional sulphonic acid esters with radiomimetic activity. Acta Unio Int Contra Cancrum. 1951; 7: 469-71.
68. Snapper I. On influence of stilbamidine upon multiple myeloma. J Mt Sinai Hosp. 1946; 13: 119-27.
69. Borel JF, Kis ZL. The discovery and development of cyclosporine (Sandimmun®). Transplant Proc. 1991; 23: 1867-74
70. Stähelin HF. The history of cyclosporine (Sandimmun®) revisited: another point of view. Experientia. 1996; 52: 5-13.
71. Heusler K, Pletscher A. The controversial early history of cyclosporin. Swiss Med Wkly. 2001; 131: 299-302.
72. Heusler K Pletscher A. The controversial early history of cyclosporine. Swiss Med Wkly. 2001; 131: 299-302.
73. Borel JF, Feurer C, Gubler HU, Stähelin HF. Biological effects of cyclosporin A: a new anti-lymphocytic agent. Agents Actions. 1976; 6: 468-75 (riprodotto anche in Agent Actions 1994; 43: 179-86).
74. Calne RY, White DJ, Thiru S, Evans DB, Mc-Master P, Dunn DC, Craddock GN, Pentlow BD, Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978; ii: 1323-7.
75. Miescher PA, Miescher A. Combined cyclosporin-steroid treatment of systemic lupus erythematosus. In: Cyclosporin in autoimmune diseases (Schindler R, ed). Berlin, Springer, 1985: 337-45.
76. Førre O, Bjerkhoel F, Salvesen CF, Berg KJ, Rugstad HE, Saelid G, Mellbye OJ, Kåss E. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum. 1987; 30: 88-92.
77. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and longterm open study of cyclosporin in Behçet's disease. Lancet. 1989; i: 1093-6.
78. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979; 301: 555.
79. Gosio B. Ricerche batteriologiche e cliniche sulle alterazioni del mais. Riv Igiene Sanità Pubblica 1896; 7: 825-68. Citato da: Bentley R. Bartolomeo Gosio, 1863-1944: an appreciation. Adv Appl Microbiol. 2001; 48: 229-50.
80. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J. 1969; 113: 515-24.
81. Jones EL, Epinette WW, Hackney WC, Menendez L, Frost P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol. 1975; 65: 537-42.
82. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T-and Bcell purine synthesis. Transplant Proc. 1990; 22: 1659-62.
83. Lipsky JJ. Mycophenolate mofetil. Lancet. 1996; 348: 1357-9.
84. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 46: 85-118.
85. Otten H. Domagk and the development of the sulphonamides. J Antimicrob Chemother. 1986; 17: 689-90.
86. Cochrane RG. A practical textbook of leprosy. London, Oxford University Press. 1947.
87. Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med. 1982; 97: 165-70.
88. Martin J, Roenigk HH, Lynch W, Tingwald FR. Relapsing polychondritis treated with dapsone. Arch Dermatol. 1976; 112: 1272-4.
89. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961; ii: 1358.
90. Lenz W. Kindliche Missbildungen nach Medikament-Einnahme während der Gravidat. Dtsch Med Wschr. 1961; 86: 2555-6.
91. Sheskin J. Therapie der Lepra-Reaktion mit Thalidomid (Eine Doppel-blind-Studie). Vorläufige Mitteilung. Hautarzt. 1966; 17: 548-9.
92. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts ist inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993; 177: 1675-80.
93. D'Amato RJ, Loughnan E, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994; 91: 4082-5.
94. Gutiérrez-Rodríguez O. Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum. 1984; 27: 1118-21.
95. Barba-Rubio J, Franco-Gonzàles F. Lupus eritematoso discoide y talidomida. Dermatologia Rev Mex. 1975; 19: 131-9.
96. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H. Thalidomide in the treatment of mucocutaneous lesions of the Behçet's syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998; 128: 443-50.
97. Ossandon A, Cassara EA, Priori R, Valesini G. Thalidomide: focus on its employment in rheumatologic diseases. Clin Exp Rheumatol. 2002; 20: 709-18.